We are live on ! Find out more
KM

Kalos Management Portfolio holdings

AUM $46.6M
1-Year Est. Return 11.52%
This Fund
S&P 500
This Quarter Est. Return
+6.13%
1 Year Est. Return
+11.52%
3 Year Est. Return
+48.48%
5 Year Est. Return
+71.6%
10 Year Est. Return
AUM
$246M
AUM Growth
-$74.8M
Cap. Flow
-$71.3M
Cap. Flow %
-28.92%
Top 10 Hldgs %
20.36%
Holding
335
New
36
Increased
107
Reduced
105
Closed
68

Sector Composition

Rank Sector Weight
1 Technology 11.78%
2 Financials 9.89%
3 Healthcare 7.55%
4 Communication Services 6.98%
5 Consumer Discretionary 5.55%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
IOVA icon
226
Iovance Biotherapeutics
IOVA
$2.04B
$212K 0.09%
8,450
FLQL icon
227
Franklin US Large Cap Multifactor Index ETF
FLQL
$1.99B
$207K 0.08%
4,856
-499
-9% -$20.9K
XLK icon
228
State Street Technology Select Sector SPDR ETF
XLK
$109B
$206K 0.08%
+2,676
New +$187K
RTX icon
229
RTX Corp
RTX
$290B
$203K 0.08%
2,347
-105
-4% -$8.84K
MAV
230
DELISTED
Pioneer Municipal High Income Advantage Fund
MAV
$198K 0.08%
16,400
QELL
231
DELISTED
Qell Acquisition Corp. Class A Ordinary Shares
QELL
$184K 0.07%
18,550
+4,600
+33% +$45.8K
VKQ icon
232
Invesco Municipal Trust
VKQ
$541M
$180K 0.07%
13,100
-450
-3% -$6.07K
BTAQ
233
DELISTED
Burgundy Technology Acquisition Corporation Class A Ordinary shares
BTAQ
$171K 0.07%
17,361
+7,250
+72% +$72K
ACIC
234
DELISTED
Atlas Crest Investment Corp.
ACIC
$158K 0.06%
15,938
NNDM
235
Nano Dimension
NNDM
$314M
$131K 0.05%
+18,212
New +$135K
ORGN
236
DELISTED
Origin Materials
ORGN
$130K 0.05%
695
-173
-20% -$51.5K
CLVS
237
DELISTED
Clovis Oncology, Inc.
CLVS
$130K 0.05%
23,750
PRTK
238
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
$127K 0.05%
19,550
CTEV
239
Claritev Corp
CTEV
$399M
$119K 0.05%
326
BNGO icon
240
Bionano Genomics
BNGO
$12.5M
$112K 0.05%
27
+8
+42% +$31.6K
OXLC
241
Oxford Lane Capital
OXLC
$862M
$109K 0.04%
2,890
-5,752
-67% -$201K
NLY icon
242
Annaly Capital Management
NLY
$17.3B
$103K 0.04%
3,072
-182
-6% -$6.61K
TWCT
243
DELISTED
TWC Tech Holdings II Corp. Class A Common Stock
TWCT
$101K 0.04%
10,250
-300
-3% -$2.98K
EQD
244
DELISTED
Equity Distribution Acquisition Corp.
EQD
$98K 0.04%
10,050
VSTM icon
245
Verastem
VSTM
$528M
$88K 0.04%
2,104
GYRE icon
246
Gyre Therapeutics
GYRE
$629M
$74K 0.03%
2,321
-54
-2% -$1.85K
AMRN
247
Amarin Corp
AMRN
$297M
$68K 0.03%
753
+238
+46% +$23.4K
CRNT icon
248
Ceragon Networks
CRNT
$188M
$42K 0.02%
+10,550
New +$37.4K
SNMP
249
DELISTED
Evolve Transition Infrastructure LP
SNMP
$33K 0.01%
701
+2
+0.3% +$50
AGRX
250
DELISTED
Agile Therapeutics
AGRX
$24K 0.01%
10

Similar funds

Kalos Management's Q2 2021 Portfolio in Review

As of Q2 2021, Kalos Management held 335 positions worth $246M, down 23% from $321M the previous quarter. Its ten largest holdings account for 20% of the portfolio.

Kalos Management withdrew a net $71.3M in Q2 2021, closing 68 positions and reducing 105 holdings. Its most notable exit was Citigroup, an estimated $2.09M position sold in full.

By sector, the portfolio is most concentrated in Technology at 12% of assets, up from 9.2% a quarter earlier, followed by Financials and Healthcare.

Against the trend, Kalos Management opened a new position in iShares US Real Estate ETF worth $2.36M.

  • Kalos Management's largest Q2 2021 buy was iShares US Real Estate ETF: 22,177 shares worth $2.36M.
  • Kalos Management added most to iShares Global Tech ETF in Q2 2021, an estimated $4.6M increase.
  • Kalos Management's biggest Q2 2021 reduction was FS KKR Capital Corp. II, cutting an estimated $11.4M.
  • Kalos Management fully exited Citigroup in Q2 2021, selling an estimated $2.09M.
  • Kalos Management's ten largest holdings make up 20% of its $246M portfolio in Q2 2021.
  • Kalos Management opened 36 new positions and closed 68 in Q2 2021.
  • Kalos Management's portfolio value fell 23% quarter-over-quarter to $246M.

Based on Kalos Management's 13F filing for Q2 2021, filed 11 Aug 2021.